In the latest issue of Clinical Endocrinology News, I found an interesting article reporting a proposal to change the name of a hormone. The rationale for the proposed change was “patient safety.” In 2009, a patient with known panhypopituitarism was admitted to a U.K. hospital for elective surgery. Diagnosis included panhypopituitarism with diabetes insipidus. The
The hormone nomenclature debate: Is a name change the key to patient safety? originally appeared in KevinMD.com.
